Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice

Y. Shirahige; R. Z. Cai; K. Szepeshazi; G. Halmos; J. Pinski; K. Groot; A. V. Schally

doi:10.1016/0753-3322(94)90007-8

Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice

Y. Shirahige, R. Z. Cai, K. Szepeshazi, G. Halmos, J. Pinski, K. Groot, A. V. Schally

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Bombesin/gastrin-releasing peptide (GRP) may be involved in the growth of human breast cancers. Nude mice bearing xenografts of MCF-7 MIII human breast cancer cell line were treated for 7 weeks with bombesin/GRP antagonists RC-3950-II and RC-3095. RC-3950-II, administered sc twice daily at a dose of 10 μg, produced significant inhibitory effects on tumor growth after 2 weeks of administration. RC-3095 acetate (D 22213), injected sc twice daily at the same dose of 10 μg, suppressed tumor growth after 4 weeks. Both RC-3950-II and RC-3095 significantly decreased the final tumor volume and tumor weights. RC-3950-I1 appeared to be somewhat more efficacious than RC-3095 in inhibiting the growth of MCF-7 MIII breast cancers. Chronic treatment with either bombesin/GRP antagonist caused down-regulation of receptors for epidermal growth factor (EGF) in tumor cell membranes, which might be related to inhibition of tumor growth. These findings suggest that bombesin/GRP antagonists should be considered for a new endocrine therapy of breast cancer.

Original language	English (US)
Pages (from-to)	465-472
Number of pages	8
Journal	Biomedicine and Pharmacotherapy
Volume	48
Issue number	10
DOIs	https://doi.org/10.1016/0753-3322(94)90007-8
State	Published - 1994
Externally published	Yes

Keywords

bombesin
breast cancer
EGF-receptor
GRP antagonists

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/0753-3322(94)90007-8

Fingerprint Dive into the research topics of 'Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice'. Together they form a unique fingerprint.

Cite this

Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice. / Shirahige, Y.; Cai, R. Z.; Szepeshazi, K.; Halmos, G.; Pinski, J.; Groot, K.; Schally, A. V.

In: Biomedicine and Pharmacotherapy, Vol. 48, No. 10, 1994, p. 465-472.

Research output: Contribution to journal › Article › peer-review

@article{53e5666faf2d4ea68071b4486dbb20af,

title = "Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice",

abstract = "Bombesin/gastrin-releasing peptide (GRP) may be involved in the growth of human breast cancers. Nude mice bearing xenografts of MCF-7 MIII human breast cancer cell line were treated for 7 weeks with bombesin/GRP antagonists RC-3950-II and RC-3095. RC-3950-II, administered sc twice daily at a dose of 10 μg, produced significant inhibitory effects on tumor growth after 2 weeks of administration. RC-3095 acetate (D 22213), injected sc twice daily at the same dose of 10 μg, suppressed tumor growth after 4 weeks. Both RC-3950-II and RC-3095 significantly decreased the final tumor volume and tumor weights. RC-3950-I1 appeared to be somewhat more efficacious than RC-3095 in inhibiting the growth of MCF-7 MIII breast cancers. Chronic treatment with either bombesin/GRP antagonist caused down-regulation of receptors for epidermal growth factor (EGF) in tumor cell membranes, which might be related to inhibition of tumor growth. These findings suggest that bombesin/GRP antagonists should be considered for a new endocrine therapy of breast cancer.",

keywords = "bombesin, breast cancer, EGF-receptor, GRP antagonists",

author = "Y. Shirahige and Cai, {R. Z.} and K. Szepeshazi and G. Halmos and J. Pinski and K. Groot and Schally, {A. V.}",

note = "Funding Information: We are grateful to Professor J Engel, ASTA Medica (Frankfurt am Main, Germany) for RC-3095 acetate (D-22213). We thank L Vallejo, L Karczewski and I Lopez for technical assistance. This work was supported by NIH Grant CA 40004 and the Medical Research Service of the Veterans Affairs, all to AVS.",

year = "1994",

doi = "10.1016/0753-3322(94)90007-8",

language = "English (US)",

volume = "48",

pages = "465--472",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson",

number = "10",

}

TY - JOUR

T1 - Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice

AU - Shirahige, Y.

AU - Cai, R. Z.

AU - Szepeshazi, K.

AU - Halmos, G.

AU - Pinski, J.

AU - Groot, K.

AU - Schally, A. V.

N1 - Funding Information: We are grateful to Professor J Engel, ASTA Medica (Frankfurt am Main, Germany) for RC-3095 acetate (D-22213). We thank L Vallejo, L Karczewski and I Lopez for technical assistance. This work was supported by NIH Grant CA 40004 and the Medical Research Service of the Veterans Affairs, all to AVS.

PY - 1994

Y1 - 1994

N2 - Bombesin/gastrin-releasing peptide (GRP) may be involved in the growth of human breast cancers. Nude mice bearing xenografts of MCF-7 MIII human breast cancer cell line were treated for 7 weeks with bombesin/GRP antagonists RC-3950-II and RC-3095. RC-3950-II, administered sc twice daily at a dose of 10 μg, produced significant inhibitory effects on tumor growth after 2 weeks of administration. RC-3095 acetate (D 22213), injected sc twice daily at the same dose of 10 μg, suppressed tumor growth after 4 weeks. Both RC-3950-II and RC-3095 significantly decreased the final tumor volume and tumor weights. RC-3950-I1 appeared to be somewhat more efficacious than RC-3095 in inhibiting the growth of MCF-7 MIII breast cancers. Chronic treatment with either bombesin/GRP antagonist caused down-regulation of receptors for epidermal growth factor (EGF) in tumor cell membranes, which might be related to inhibition of tumor growth. These findings suggest that bombesin/GRP antagonists should be considered for a new endocrine therapy of breast cancer.

AB - Bombesin/gastrin-releasing peptide (GRP) may be involved in the growth of human breast cancers. Nude mice bearing xenografts of MCF-7 MIII human breast cancer cell line were treated for 7 weeks with bombesin/GRP antagonists RC-3950-II and RC-3095. RC-3950-II, administered sc twice daily at a dose of 10 μg, produced significant inhibitory effects on tumor growth after 2 weeks of administration. RC-3095 acetate (D 22213), injected sc twice daily at the same dose of 10 μg, suppressed tumor growth after 4 weeks. Both RC-3950-II and RC-3095 significantly decreased the final tumor volume and tumor weights. RC-3950-I1 appeared to be somewhat more efficacious than RC-3095 in inhibiting the growth of MCF-7 MIII breast cancers. Chronic treatment with either bombesin/GRP antagonist caused down-regulation of receptors for epidermal growth factor (EGF) in tumor cell membranes, which might be related to inhibition of tumor growth. These findings suggest that bombesin/GRP antagonists should be considered for a new endocrine therapy of breast cancer.

KW - bombesin

KW - breast cancer

KW - EGF-receptor

KW - GRP antagonists

UR - http://www.scopus.com/inward/record.url?scp=0028588054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028588054&partnerID=8YFLogxK

U2 - 10.1016/0753-3322(94)90007-8

DO - 10.1016/0753-3322(94)90007-8

M3 - Article

C2 - 7858155

AN - SCOPUS:0028588054

VL - 48

SP - 465

EP - 472

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 10

ER -